Early safety check for new chikungunya drug

NCT ID NCT04441905

Completed Knowledge-focused Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a single dose of an experimental drug called SAR440894 in 42 healthy adults to see if it was safe. The goal was not to treat the disease but to gather initial safety information before testing it in people with chikungunya virus infection. Participants were monitored for side effects over about 150 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chikungunya prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHIKUNGUNYA VIRUS INFECTION

Contacts and locations

Show contact details

Locations

Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit

Durham, North Carolina, 27710, United States
PPD - Austin Clinical Research Unit

Austin, Texas, 78744-1645, United States
Pharmaceutical Product Development - Orlando Clinical Research Unit

Orlando, Florida, 32806, United States